美国FDA已经批准Millennium公司的蛋白酶抑制剂bortezomib(Velcade)作为顽固性或易复发的多发性骨髓瘤的治疗药物。公司表示 ,该药物于 2 0 0 3年 6月投入市场 ,这将使抗癌药物治疗进入一个崭新的阶段。依据bortezomibⅡ期临床试验数据 ,仅在该药提出申请后 4个月 ,通过FDA加速 The U.S. FDA has approved Millennium’s protease inhibitor bortezomib (Velcade) as a treatment for refractory or relapsed multiple myeloma. The company said the drug was brought to the market in June 2003 and will put anticancer drug treatment in a completely new phase. Based on bortezomib Phase II clinical trial data, accelerated by FDA only 4 months after the drug was filed